Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Kyle LaHucik

Senior Reporter

Newleos Therapeutics emerged Thursday with $93.5 million and a bundle of oral small molecules that it licensed from Roche, further demonstrating that the pharma-to-startup pipeline …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

NIH’s funding cut plan poses challenges for researchers despite court halt

AbbVie pens another T cell engager deal, this time with Xilio

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

Novo's weight loss drug helps curb some drinking habits, small study shows

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs